Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study With Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary and Secondary Central Nervous System Lymphoma

NCT04462328 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04462328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study With Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary and Secondary Central Nervous System Lymphoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 29, 2021
Completion date
September 30, 2028
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma